Cytotoxic T-lymphocyte-associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer.

Cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) is an immunoregulatory molecule expressed by activated T cells and resting CD4CD25 T cells. In patients with advanced melanoma, our group reported that administration of anti-CTLA-4 antibody mediated objective cancer regression in 13% of patients. This study also established that the blockade of CTLA-4 was associated with grade III/IV autoimmune manifestations that included dermatitis, enterocolitis, hepatitis, uveitis, and a single case of hypophysitis. Since this initial report, 7 additional patients with anti-CTLA-4 antibody-induced autoimmune hypophysitis have been accumulated. The characteristics, clinical course, laboratory values, radiographic findings, and treatment of these 8 patients are the focus of this report.

[1]  A. Olivi,et al.  Autoimmune hypophysitis. , 2020, Endocrine reviews.

[2]  S. Rosenberg,et al.  Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  P. Attia,et al.  Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-CTLA-4 , 2005 .

[4]  S. Groshen,et al.  Autoimmunity in a phase I trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and Montanide ISA 51 for patients with resected stages III and IV melanoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  C. Cockram,et al.  Panhypopituitarism in association with interferon-alpha treatment. , 2004, Singapore medical journal.

[6]  Thomas A. Davis,et al.  Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[7]  Luc J. Smink,et al.  Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease , 2003, Nature.

[8]  Thomas Davis,et al.  Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[9]  J. Schramm,et al.  Lymphocytic hypophysitis: non-invasive diagnosis and treatment by high dose methylprednisolone pulse therapy? , 1999, Journal of neurology, neurosurgery, and psychiatry.

[10]  D. Bernasconi,et al.  Lymphocytic hypophysitis. Case report. , 1999, Journal of neurosurgical sciences.

[11]  E. Seidman,et al.  Severe autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy in an adolescent girl with a novel AIRE mutation: response to immunosuppressive therapy. , 1999, The Journal of clinical endocrinology and metabolism.

[12]  T. Sullivan,et al.  Lymphoproliferation in CTLA-4-deficient mice is mediated by costimulation-dependent activation of CD4+ T cells. , 1997, Immunity.

[13]  H. Griesser,et al.  Lymphoproliferative Disorders with Early Lethality in Mice Deficient in Ctla-4 , 1995, Science.

[14]  J. Bluestone,et al.  Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. , 1995, Immunity.

[15]  S. Asa,et al.  Clinical case seminar: lymphocytic hypophysitis: clinicopathological findings. , 1995, The Journal of clinical endocrinology and metabolism.

[16]  G. Eisenbarth,et al.  Isohormonal therapy of endocrine autoimmunity. , 1995, Immunology today.

[17]  R. B. Goudie,et al.  Anterior hypophysitis and Hashimoto's disease in a young woman. , 1962, The Journal of pathology and bacteriology.